1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016" provides an overview of Alpha- Antitrypsin Deficiency clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha- Antitrypsin Deficiency. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials 26
Prominent Drugs 28
Latest Clinical Trials News on Alpha- Antitrypsin Deficiency 29
Dec 02, 2016: The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency 29
Nov 14, 2016: Arrowhead Pharmaceuticals Presents New Data on ARC-AAT 29
Oct 20, 2016: Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting 30
Clinical Trial Profile Snapshots 31
Appendix 58
Abbreviations 58
Definitions 58
Research Methodology 59
Secondary Research 59
About GlobalData 60
Contact Us 60
Disclaimer 60
Source 61

List of Tables
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Region, 2016* 6
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 12
Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, G7 Countries (%), 2016* 13
Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, E7 Countries (%), 2016* 16
Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Phase, 2016* 19
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 20
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
Alpha- Antitrypsin Deficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 24
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 12
Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, G7 Countries (%), 2016* 13
Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, E7 Countries (%), 2016* 16
Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Phase (%), 2016* 19
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 20
Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
Alpha- Antitrypsin Deficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 24
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • October 2016
  • by Grand View Research

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one ...

Anti-Infectives Market Analysis & Trends - Product (Antibacterials, Antifungals and Antivirals) - Forecast to 2025

Anti-Infectives Market Analysis & Trends - Product (Antibacterials, Antifungals and Antivirals) - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Anti-Infectives Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $190.28 billion by 2025. Some of the prominent trends that the market is witnessing ...

Global and Chinese Zidovudine (CAS 30516-87-1) Industry, 2017 Market Research Report

Global and Chinese Zidovudine (CAS 30516-87-1) Industry, 2017 Market Research Report

  • $ 3000
  • Industry report
  • February 2017
  • by Prof Research

The 'Global and Chinese Zidovudine Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Zidovudine industry with a focus on the Chinese market. ...


Download Unlimited Documents from Trusted Public Sources

HIV AIDS Statistics and Antiviral Market in the US

  • February 2017
    31 pages
  • HIV AIDS  

    Antiviral  

  • United States  

View report >

HIV AIDS Statistics and HIV Antiviral Market in China

  • February 2017
    11 pages
  • HIV AIDS  

    Infectious Dise...  

    HIV Antiviral  

  • China  

    United States  

View report >

Anesthetics and Therapy Market in the US

  • February 2017
    9 pages
  • Anesthetics  

    Therapy  

  • United States  

View report >

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.